|Day Low/High||74.63 / 75.30|
|52 Wk Low/High||49.87 / 76.31|
FDA 510(k) Clearance for CoRoent® Small Interbody™ System Includes Indication for Treatment of Cervical Disc Degeneration at up to Four Contiguous Levels
NICE Guidance Supported by Literature Review of More than 200 Peer-Reviewed Articles Primarily Reflecting Experience with NuVasive's Industry-Leading XLIF Procedure
This patient-monitoring device-maker has plenty of room for growth.
The most recent short interest data was recently released for the 01/13/2017 settlement date, and Nuvasive Inc is one of the most shorted stocks of the Russell 3000, based on 6.67 "days to cover" versus the median component at 5.04. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.
Cramer shares his views on takeover talks. NXP Semiconductor, Apple and Citigroup are among the stocks discussed.
PNR, PCAR, NUVA, TUP and CREE all were recently downgraded by TheStreet's Quant Ratings.
But several airline and retail stocks are proving highly volatile.
NuVasive (NUVA) reported light revenue for the 2016 third quarter late Tuesday.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: HNP, QTS, SRLP, TCBI, UA, ZIXI Downgrades: BGSF, BXP, CAT, CIT, NUVA, PCAR, PNR, VLO Initiations: JAX Read on to get TheStreet Quant Ratings' detailed report:
These stocks rising on unusual volume are within range of triggering big breakout trades.
The medical device company taps Jason Hannon, an 11-year company veteran, as its new president and COO, succeeding Patrick Miles, who was appointed vice chairman.
Medical technology companies are hot, says Rich Newitter, managing director at Leerink.
Medical technology companies are hot and not even climbing price-to-earnings multiples will slow down the likes of Hologic, Zimmer Biomet, Zeltiq and NuVasive.
These four small-cap stocks would be a healthy addition to your portfolio, says David Swank, portfolio manager for the Hood River Small-Cap Growth Fund.
Zimmer's return to growth is fueling acquisition thoughts by analysts. There are a number of possibilities.
Zimmer Biomet is on track to return to growth, which could signal more mergers and acquisitions within the industry.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AWRE, CRD.B, NUVA, SIRI, SNBC, TI, TI.A, TNC Downgrades: DD, HOT, TRNS, TROW, ZIXI Initiations: TRU, XTLY, YECO Read on to get TheStreet Quant Ratings' detailed report:
Trade-Ideas LLC identified NuVasive (NUVA) as a new lifetime high candidate
Here are Wednesday's top research calls, including an upgrade for Pandora, and downgrades for Darden Restaurants, MetLife and Yelp.
This group of nibblers triggered a modest reversal leading into the Fed’s late-afternoon minutes.
These medical device makers could be acquisition targets (and one buyer) following Zimmer Biomet's takeout of LDR Holding. Their charts are also buys, says technical chartist Bruce Kamich.
The $1 billion transaction could inspire other medical device companies and private equity firms to bend over backwards for spinal device assets.
The hefty premium Zimmer Biomet is paying in the $1 billion deal for the spine company suggests the target's management followed a competitive process.